ABT earnings

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE:ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GA

ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpointABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025. Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-re

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increaseABBOTT PARK, Ill., Oct. 15, 2025  /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2025. Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.Third-quarter GAAP diluted EPS of $0.94 and ad

ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at https://www.abbott.com/investors.html. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in dia

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on August 27th Equities are up this morning as investors wait for chip giant Nvidia's Q2 earnings report. The company is set to release the earnings after market close this afternoon.As the most heavily weighted company in the S&P 500 at more than 8%, Nvidia's results will likely be felt by investors throughout the rest of the week and provide insight into the level of demand for AI.The

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ --  Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe

ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi

Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billionFourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024. Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and 10.1 percent on an organic basis

ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical dataABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2024. Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding

ABBOTT PARK, Ill., Sept. 25, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medic

Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with new product approvalsABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS

ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2024. First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.Abbott narrowed its full-year 2024 EPS guidance range. Abbott projects full-year diluted

Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percentFull-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underlying base business increased 11.6 percentFull-year 2023 GAAP diluted EPS of $3.26; adjusted diluted EPS of $4.44R&D pipeline continues to deliver steady cadence of new productsABBOTT PARK, Ill., Jan. 24, 2024 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023. Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 perce

ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

ABBOTT PARK, Ill., Sept. 27, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medic

Sales of $10.0 billion driven by strong underlying base business performance Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 11.5 percent, led by Medical Devices, Established Pharmaceuticals and NutritionContinues to strengthen portfolio with new product approvals and expanded reimbursement coverageABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2023. Second-quarter GAAP diluted EPS of $0.78 and adjusted diluted EPS of $1.08, which excludes specified items.Projected full-year 2023 di

ABBOTT PARK, Ill., June 29, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2023 financial results on Thursday, July 20, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, m

Sales of $9.7 billion driven by strong underlying base business performance Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and NutritionABBOTT PARK, Ill., April 19, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2023. First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03, which excludes specified items.Projected full-year 2023 diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 remains unchanged.Projecte

ABBOTT PARK, Ill., March 29, 2023 /PRNewswire/ -- Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-c

Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billionFull-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percentFull-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34Continues to strengthen portfolio with steady cadence of new product approvalsABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022. Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of

ABBOTT PARK, Ill., Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

Worldwide sales of $10.4 billion in the third quarterRaises full-year earnings-per-share guidanceContinues to strengthen portfolio with new product approvals and launchesABBOTT PARK, Ill., Oct. 19, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2022. Third-quarter sales of $10.4 billion decreased 4.7 percent on a reported basis and increased 1.3 percent on an organic basis, which excludes the impact of foreign exchange.GAAP diluted EPS1 was $0.81 in the third quarter. Excluding specified items, adjusted diluted EPS was $1.15.Abbott is raising its full-year 2022 EPS guidance. Abbott projects full-year diluted EPS on a GAAP basis

ABBOTT PARK, Ill., Sept. 28, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

Sales growth of 10.1 percent; organic sales growth of 14.3 percentGAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percentGlobal COVID-19 testing-related sales of $2.3 billion in the second quarterContinues to strengthen portfolio with new product approvalsABBOTT PARK, Ill., July 20, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2022. Second-quarter sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis, which excludes the impact of foreign exchange.GAAP diluted EPS1 was $1.14 in the second quarter. Excluding specified items, adjusted diluted EPS was $1

ABBOTT PARK, Ill., June 29, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

Sales growth of 13.8 percent; organic sales growth of 17.5 percentGlobal COVID-19 testing-related sales of $3.3 billion in the first quarterExcluding COVID-19 testing-related sales, first-quarter reported sales growth of 3.9 percent and organic sales growth of 7.7 percentGAAP diluted EPS growth of 37.0 percent; adjusted diluted EPS growth of 31.1 percentContinues to strengthen portfolio with new product approvals and expanded reimbursement coverageABBOTT PARK, Ill., April 20, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2022. First-quarter sales of $11.9 billion increased 13.8 percent on a reported basis and 17.5 percent on an

ABBOTT PARK, Ill., March 28, 2022  /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2022 financial results on Wednesday, April 20, 2022, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostic

ABBOTT PARK, Ill., Jan. 26, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022. Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange. Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32. Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21, reflecting 42.7% growth versus the prior year.1 Global COVID-19 testing-related sales were

ABBOTT PARK, Ill., Jan. 4, 2022 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2021. Third-quarter sales of $10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis, which excludes the impact of foreign exchange. Third-quarter GAAP diluted EPS was $1.17 and adjusted diluted EPS, which excludes specified items, was $1.40, reflecting 42.9 percent growth versus the prior year.1 Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of $3.55 to $3.65 and full-year adjusted diluted EPS from continuing operations of $5.00 to $5.10, reflecting growth of 38.4 percent at the

ABBOTT PARK, Ill., Sept. 23, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics

ABBOTT PARK, Ill., July 22, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2021. Second-quarter sales of $10.2 billion increased 39.5 percent on a reported basis and 35.0 percent on an organic basis, which excludes the impact of foreign exchange. Second-quarter GAAP diluted EPS was $0.66 and adjusted diluted EPS, which excludes specified items, was $1.17, reflecting 105.3 percent growth versus the prior year.1 Abbott continues to project full-year 2021 diluted EPS from continuing operations on a GAAP basis of $2.75 to $2.95 and full-year adjusted diluted EPS from continuing operations of $4.30 to $4.50, reflecting strong, double